{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000038","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.212861+00:00","generated_at":"2026-05-31T13:09:31.007983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track","bullets":["VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.","Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.","Cash and investments $628.9M at June 30, 2024; strong balance sheet.","On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).","Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000038","json":"https://secwatch.observer/filing/0001711279-24-000038.json","markdown":"https://secwatch.observer/filing/0001711279-24-000038.md","text":"https://secwatch.observer/filing/0001711279-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/0001711279-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/krys-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:09:31.007983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}